Why this small study matters
Type 2 Usher syndrome (USH2) is an inherited condition that combines hearing loss with retinitis pigmentosa (RP), a progressive retinal disease that commonly affects night vision and peripheral vision. For people with USH2 and their families, difficulties in dim light can be among the earliest and most disruptive visual symptoms. They may affect moving around safely at dusk, navigating unfamiliar places, and maintaining independence.
A 2026 prospective case series in the Journal of Clinical Medicine explored an unusual potential treatment approach: stimulating the ophthalmic nerve, combined with intravenous ascorbic acid (vitamin C). The researchers were interested in whether this strategy could improve symptoms thought to be connected with dysregulated blood flow in the eye and inner ear.
The study is early-stage and involved only nine participants. Still, its findings offer a preliminary signal that this combined approach may improve patients’ self-reported ability to function in low-light conditions. Importantly, the authors emphasize that controlled studies with objective vision and hearing measures are now needed.
What treatment was studied?
All nine participants with USH2 received daily ophthalmic nerve stimulation (ONS) together with intravenous ascorbic acid (AA) for two weeks. The ophthalmic nerve is a branch of the trigeminal nerve, which carries sensation from areas including the forehead and upper face. In this study, ONS was investigated as a way to potentially influence ocular and cochlear blood flow—the circulation serving the eye and the hearing structures of the inner ear.
The study was prospective and open-label. “Prospective” means participants were followed forward in time after treatment. “Open-label” means both participants and investigators knew the treatment being given. There was no untreated or placebo comparison group.
The main outcome was change at six months in a 10-item Low Luminance Questionnaire (LLQ-10). This questionnaire asks about a person’s perceived ability to carry out activities in low-light conditions. Scores range from 0 to 100, with higher scores indicating better self-reported scotopic, or dim-light, function.
The key findings: improved self-reported night vision
At six months, the group’s LLQ-10 score improved by an average of 42.1 points, with a reported statistical significance of p = 0.0001. Seven of the nine participants—77.8%—met the study’s definition of a responder: an increase of at least 25 points on the LLQ-10.
In everyday terms, these findings suggest that many participants felt their night-vision function had improved substantially after the treatment course. Because low-light vision is a major concern in RP and USH2, this result is the most notable finding from the study.
The researchers also measured best-corrected visual acuity (BCVA), which evaluates sharpness of central vision with the best possible glasses or contact-lens correction, and contrast sensitivity (CS), which reflects the ability to distinguish objects from their background when contrast is limited. Clinically meaningful improvements in visual acuity and contrast sensitivity were seen in 22.2% of tested eyes. These improvements occurred in a subset rather than across all tested eyes.
One-third of participants also reported subjective improvement in hearing function. This is of particular interest in USH2, where hearing involvement is a defining feature. However, hearing changes in this report were based on participant reports rather than objective audiometric testing.
No severe adverse events were reported during the study.
How should patients and families interpret these results?
The results are encouraging, but they do not yet establish that ONS plus intravenous ascorbic acid is an effective treatment for USH2 or RP. The study was very small, included no control group, and relied primarily on a patient-reported outcome for its main endpoint. In an open-label study, expectations, changes in symptom awareness, and other factors can influence self-reported outcomes.
In addition, USH2 is genetically and clinically diverse. A treatment effect seen in nine people cannot show which individuals may benefit, how durable any improvement may be, or whether the approach changes the underlying progression of retinal degeneration.
Nevertheless, the study highlights an important broader idea in RP research: treatment strategies may extend beyond directly targeting the disease-causing gene. Researchers are also investigating pathways that could affect retinal function, including the environment surrounding retinal cells and mechanisms that may influence blood flow.
What comes next?
The authors call for controlled trials that include objective scotopic testing—formal tests of vision in dim light—and audiometric testing of hearing. These next studies will be essential for determining whether the reported functional changes can be confirmed with standardized measurements and whether they are greater than changes seen without active treatment.
Future research will also need to assess the durability of effects, the most appropriate treatment schedule, and safety in larger and more diverse groups of people with USH2. For the RP community, this case series represents an early clinical observation rather than a proven therapy. Its value lies in generating a testable new direction: whether modulating pathways linked to ocular and cochlear blood flow can meaningfully support visual and hearing function in Usher syndrome.

